Cool News Features

Pharmacy Times® interviewed Caroline Carney, MD, MSc, FAPM, CPHQ, chief medical officer of Magellan Health, a board-certified internist, and a board-certified psychiatrist, to discuss the correlation between heart health and mental health.

Pharmacy Times® interviewed Caroline Carney, MD, MSc, FAPM, CPHQ, chief medical officer of Magellan Health, a board-certified internist, and a board-certified psychiatrist, to discuss the correlation between heart health and mental health in women aged 65 years and older.

Pharmacy Times® interviewed Caroline Carney, MD, MSc, FAPM, CPHQ, CMO of Magellan Health, on some of the issues surrounding the understanding of mental health and brain health today.

It was one of those rare occasions in school where we were allowed to sit on the floor, making it feel like a special day. Sitting with my legs crossed on the itchy industrial carpeting, I pressed my back up against the painted cinder block wall, which offered a cool reprieve from the stuffy classroom.

Changes that are taking place during the COVID-19 pandemic could persist and significantly reshape the specialty pharmacy industry, experts believe.

Dr. Caroline Carney, the chief medical officer for Magellan Rx Management, talks to ABC15 about the anxiety surrounding coronavirus and how to speak to your children about their fears.

In 1949, Dr Linus Pauling coined the term molecular disease when describing sickle cell anemia in a landmark paper published in Science. Using electrophoresis, Dr Pauling and colleagues demonstrated that sickle cell anemia was caused by an abnormal form of hemoglobin.

Magellan Rx is a next-generation full-service pharmacy benefit manager that has over 40 years of expertise helping customers and members solve complex pharmacy challenges. Recognizing unused opioid medication kept by patients in their households can be diverted to inappropriate use, Magellan launched an Opioid Disposal texting program. The solution connects a digital pain management program to a physical pouch-disposal program.

At AMCP 2019, Kristin D. Brown-Gentry, MS, senior health outcomes scientist, Magellan Rx Management, talks about using predictive analytics to optimize pharmaceutical outcomes.

With new factors continuing to emerge every day in the growing opioid epidemic, now is the time to take proactive measures to better protect communities across the nation. Through education, support for evidence-based treatment and naloxone access, and partnership with families, providers, and community service agencies, we can help ensure those with OUD receive the right support at the right time, putting them back on a path of sobriety and health.

With deadly attacks in our communities and schools becoming more commonplace, increasingly more common natural disasters, and a number of military conflicts in the last decade, it’s no surprise that 70 percent of U.S. adults have experienced a traumatic event in their lifetime.

Technology allows for additional avenues to engage with patients and make us more available to them, explained Brian MacDonald, PharmD, manager, Specialty Clinical Programs, Magellan Rx Management.

Healthcare executives should continue to monitor specialty medical pharmacy claim information and trends, according to Eric McKinley, PharmD, director, specialty clinical solutions at Magellan Rx Management.

In recent years, artificial intelligence (AI) has weaved its way into the very fabric of our daily lives, providing personalized product recommendations, shaping our social media feeds, and even calculating our quickest route to work.

The commercial per-member-per-month (PMPM) spending rate increase on medical pharmacy totalled 18% between 2016 and 2017, 4% higher than the five-year average, according to a new report from Magellan Rx Management released Tuesday morning.

Magellan Rx Management, the pharmacy benefit management arm of managed-care company Magellan Health, released its ninth annual trend report diving into spending on drugs administered by providers, and it found that per-member, per-month spending on these therapies increased by 18% from 2016 to 2017, reaching an average of $29.97 monthly, for people enrolled in commercial plans.